HC Wainwright Brokers Lower Earnings Estimates for BrainsWay

BrainsWay Ltd. (NASDAQ:BWAY) – Equities researchers at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for BrainsWay in a research note issued on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.18 per share for the year, down from their prior estimate of $0.32. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.

BrainsWay Stock Performance

Shares of BWAY stock opened at $10.21 on Monday. The firm has a market capitalization of $192.22 million, a price-to-earnings ratio of 102.11 and a beta of 1.29. The firm’s 50 day moving average is $10.27 and its 200-day moving average is $9.64. BrainsWay has a 1 year low of $4.61 and a 1 year high of $11.79.

Institutional Investors Weigh In On BrainsWay

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new stake in BrainsWay during the 4th quarter worth about $44,000. JPMorgan Chase & Co. grew its position in shares of BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after buying an additional 11,221 shares during the period. Sei Investments Co. bought a new stake in shares of BrainsWay during the fourth quarter worth approximately $149,000. Cubist Systematic Strategies LLC raised its stake in shares of BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after buying an additional 2,446 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after buying an additional 2,144 shares during the period. Institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.